Legacy health and science information resources have long served as a foundation for public understanding of disease risk, typically emphasizing general wellness and broad epidemiological patterns. Within this tradition, audiences are accustomed to content that contextualizes health outcomes without venturing into specific mechanistic or causal claims. As we pivot toward a more targeted inquiry, the focus narrows to the relationship between pharmaceutical exposure and subsequent disease development. In particular, the transition from general health literacy to occupational or therapeutic exposure concern requires careful framing. Here, the legacy heritage of neutral, evidence-informed discourse provides a stable platform for examining whether a specific intervention—such as Avelumab administration—may be associated with an increased risk of Merkel Cell Carcinoma. This shift does not assert causation but rather opens a disciplined line of questioning: given that Avelumab is an immune checkpoint inhibitor used in oncology, and that Merkel Cell Carcinoma is a rare skin cancer with viral and environmental risk factors, the occupational exposure concern emerges when considering patients or workers who receive or handle this drug. The bridge concept thus moves from general health awareness to a focused, risk-oriented inquiry, maintaining academic neutrality while acknowledging the practical implications for those with direct exposure.
Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is characterized by high rates of recurrence and mortality, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). Clinically, MCC presents as a rapidly growing, painless, firm, dome-shaped nodule on sun-exposed skin, often mistaken for a benign cyst or other skin lesion. Diagnosis is confirmed by histopathology and immunohistochemistry, typically showing neuroendocrine markers such as cytokeratin 20 and chromogranin A. Given its aggressive nature, early detection and treatment are critical.
Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It functions as an immune checkpoint inhibitor, blocking the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby enhancing the immune system's ability to attack cancer cells. Avelumab is approved in the USA, the EU, and Japan for the treatment of metastatic MCC, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the JAVELIN Merkel 200 trial, a two-part, single-arm, phase II study in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). As with other checkpoint inhibitors, avelumab can cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). Reported irAEs include dermatitis, colitis, hepatitis, pneumonitis, endocrinopathies, and, in rare cases, reactivation of sarcoidosis (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, the development of MCC itself as an adverse effect of avelumab is not documented in the available evidence.
The evidence does not support a causal mechanism by which avelumab induces or causes MCC. Instead, avelumab is a treatment for MCC. The drug's mechanism of action—blocking PD-L1 to enhance anti-tumor immunity—is intended to treat existing MCC, not to cause it. The evidence indicates that immune checkpoint inhibition, including with avelumab, has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Furthermore, for patients who become refractory to avelumab, subsequent treatment with ipilimumab plus nivolumab has shown efficacy (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). These findings underscore that avelumab is used to treat MCC, not to cause it.
Given that avelumab is an approved therapy for MCC, warnings about the drug focus on its adverse effects, such as irAEs, rather than on causing MCC. The evidence does not indicate that avelumab is associated with an increased risk of developing MCC. Therefore, warnings regarding avelumab and MCC are adequate in that they do not suggest a causal link. However, patients and clinicians should be aware that approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors, including avelumab, may progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). This progression is a failure of treatment, not a drug-induced causation of the disease. For patients who develop MCC after exposure to avelumab, causation is unlikely because avelumab is a treatment for MCC, not a risk factor. The temporal relationship between avelumab exposure and MCC diagnosis would typically involve the drug being administered after the diagnosis of MCC. In the rare scenario where a patient develops MCC while on avelumab for another indication, the evidence does not support a causal link. The known risk factors for MCC—ultraviolet light exposure and Merkel cell polyoma virus—are more plausible explanations. The evidence does not document any cases where avelumab exposure preceded the development of MCC. Instead, the timeline in the literature shows that avelumab is administered after MCC diagnosis. For example, in the JAVELIN Merkel 200 trial, patients with pre-existing metastatic MCC received avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). In studies of avelumab-refractory patients, the drug was given after MCC was already present (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). Thus, there is no evidence of a timeline where avelumab exposure leads to MCC harm.
Based on the available evidence, avelumab does not cause Merkel cell carcinoma. Rather, it is an effective treatment for this disease. The drug's pharmacology, clinical trial data, and post-marketing experience all support its role as a therapeutic agent, not a causative factor. Warnings about avelumab appropriately address its immune-related adverse effects, and there is no evidence to suggest that patients are at risk of developing MCC from avelumab exposure. Causation considerations should focus on established risk factors, such as ultraviolet light and Merkel cell polyoma virus, rather than on avelumab.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
No, the available evidence does not support that Avelumab causes Merkel cell carcinoma. Avelumab is an immune checkpoint inhibitor used to treat metastatic Merkel cell carcinoma, not to cause it. Clinical trials and post-marketing data show it is an effective therapy for this disease.
The primary risk factors for Merkel cell carcinoma are chronic exposure to ultraviolet light and infection with the Merkel cell polyoma virus. These factors are well-established in the medical literature (https://pubmed.ncbi.nlm.nih.gov/35877101/).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.